NEW YORK (GenomeWeb News) — Qiagen on Monday said it has licensed real-time PCR technology from Roche and from Ortho Clinical Diagnostics.
Under the agreement with Roche, Qiagen said it expands an existing arrangement to include all of Roche’s RT-PCR patents and pending patents. Qiagen said the agreement includes rights to patents for enzymes, improved PCR, and pathogen-specific patents.
Through the Ortho agreement, Qiagen has licensed rights to patents for a taq-polymerase antibody method that speeds up the activation of PCR enzymes in the early phases of the process.
Qiagen said that these licenses expand its portfolio of assays and diagnostics using “almost any” basic IVD-related PCR and real-time PCR.
Financial terms of the agreements were not released.